Halia Therapeutics Published in Journey of Drug Targeting
August 28, 2025
A Halia publication has been featured in the Journey of Drug Targeting: “Ofirnoflast (HT-6184): A first-in-class, orally bioavailable NEK7 inhibitor currently undergoing Phase 2 clinical evaluation.” Ofirnoflast targets inflammation at its source by preventing NLRP3 inflammasome formation and promoting its disassembly – essentially disrupting the root cause rather than just managing symptoms.
Recent News
- Nucleus Institute Convergence Point Groundbreaking
- EDWARDS LIFESCIENCES RECEIVES FDA APPROVAL FOR AUTUS VALVE
- Route 92 Medical Announces U.S. FDA Clearance for the FreeClimb® 46 Catheter with Tenzing® 4
- Owlet Announces Creation of Baby Safety Task Force to Educate, Innovate, and Advocate for Better Baby Safety Standards
- BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
- Freyya Closes Oversubscribed Pre-Seed Financing to Advance FDA Regulatory Milestones, Commercialization
